Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00562159
First received: November 20, 2007
Last updated: November 10, 2014
Last verified: November 2014

November 20, 2007
November 10, 2014
November 2007
September 2009   (final data collection date for primary outcome measure)
Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS) [ Time Frame: Start of the GPS to End of the GPS ] [ Designated as safety issue: No ]
The TCS is the sum of the rhinoconjunctivitis daily symptom score (DSS) and rhinoconjunctivitis daily medication score (DMS) averaged over the entire GPS. The TCS ranged from 0-54, with increasing score indicating a higher level of symptom severity. The DSS is composed of 6 rhinoconjunctivitis symptoms with scores from 0-18, with increasing score indicating increased severity. The DMS is composed of a sum of the scores associated with rescue medication use per day. The range for the DMS was 0-36, with a lower score indicating less use of rescue medication.
  • The average rhinoconjunctivitis daily medication score (DMS). [ Time Frame: Over the entire grass pollen season (GPS) (approximately 3 months) ]
  • The average rhinoconjunctivitis daily symptom score (DSS). [ Time Frame: Over the entire grass pollen season (GPS) (approximately 3 months) ]
Complete list of historical versions of study NCT00562159 on ClinicalTrials.gov Archive Site
  • Participant Average Rhinoconjunctivitis Daily Symptom Score (DSS) Over the Entire GPS [ Time Frame: Start of the GPS to End of the GPS ] [ Designated as safety issue: No ]
    The DSS is composed of six rhinoconjunctivitis symptoms which were recorded daily including runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy, and watery eyes, and the symptoms were measured on a scale of 0 (no symptom) to 3 (severe symptoms). A higher score indicated a higher level of symptoms and the total daily score could range from 0 to 18.
  • Participant Average Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire GPS [ Time Frame: Start of the GPS to End of the GPS ] [ Designated as safety issue: No ]
    The DMS is composed of a sum of the scores associated with rescue medication use per day. Rescue medications were implemented when a participant had a symptom score >= 4. Rescue medications for allergic rhinoconjunctivitis were to be utilized in a step-wise fashion: loratadine, olopatadine hydrochloride 0.1% opthalmic solution, mometasone, and prednisone, in that sequence. The score for the DMS ranged from 0-36. A lower medication score indicated less impact on symptomology and was suggestive of less use of rescue medication.
  • Participant Average Weekly Rhinoconjunctivitis Quality-of-Life Questionnaire With Standardized Activities (RQLQ(S)) Total Score Over the Entire GPS [ Time Frame: Start of the GPS to End of the GPS ] [ Designated as safety issue: No ]
    The RQLQ(s) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment.
  • The average rhinoconjunctivitis DSS for the peak GPS. [ Time Frame: Over the entire/peak grass pollen season. ]
  • The average rhinoconjunctivitis DMS for the peak GPS. [ Time Frame: Over the entire/peak grass pollen season. ]
  • The average weekly rhinoconjunctivitis quality of life total score for the entire GPS [ Time Frame: Over the entire/peak grass pollen season. ]
  • The percentage of minimal symptom days during the entire GPS. [ Time Frame: Over the entire/peak grass pollen season. ]
Not Provided
Not Provided
 
Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Grass (Phleum Pratense) Sublingual Tablet (SCH 697243) in Adult Subjects With a History of Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study in participants 18 to 65 years of age, of either sex, and of any race with a history of grass pollen induced rhinoconjunctivitis with or without asthma. While receiving treatment, participants will receive either grass sublingual tablet or placebo. Open-label rescue medications for the hinoconjunctivitis and asthma symptoms will be provided. Participants will visit the study site for at least 12 visits. A total of 10 allergic symptoms, 6 rhinoconjunctivitis and 4 lung symptoms, will be recorded daily on an electronic diary by the participant.

The start and end of the grass pollen season (GPS) was determined based on the regional grass pollen count, and lasted up to 162 days. For each region, the GPS is defined as the first day of 3 consecutive recorded days with a grass pollen count of ≥ 10 grains/m^3, to the last day of the last occurrence of 3 consecutive recorded days with a grass pollen count ≥ 10 grains/m^3, inclusively.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Rhinoconjunctivitis
  • Rhinitis
  • Conjunctivitis
  • Allergy
  • Drug: Placebo
    Placebo sublingual tablet
  • Biological: SCH 697243
    SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
    Other Name: Phleum pratense extract
  • Drug: Loratadine 10 mg Rescue Treatment
    Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
    Other Name: Claritin
  • Drug: Olopatadine 0.1% Rescue Treatment
    Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
    Other Name: Pantanol
  • Drug: Mometasone 50 mcg Rescue Treatment
    Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
    Other Name: Nasonex
  • Drug: Prednisone 5 mg Rescue Treatment

    Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day

    (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray.

    Other Names:
    • Deltasone
    • Meticorten
    • Orasone
    • Prednicen-M
    • Prednicot
    • Sterapred
    • Sterapred DS
  • Drug: Albuterol sulfate 108 mcg
    Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
    Other Names:
    • Proventil
    • Ventolin
    • Volmax
    • Vospire
  • Drug: Fluticasone propionate 44 mcg
    Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
    Other Name: Flonase
  • Drug: Prednisone 5 mg
    Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
    Other Names:
    • Deltasone
    • Meticorten
    • Orasone
    • Prednicen-M
    • Prednicot
    • Sterapred
    • Sterapred DS
  • Placebo Comparator: Placebo
    Matching Placebo
    Interventions:
    • Drug: Placebo
    • Drug: Loratadine 10 mg Rescue Treatment
    • Drug: Olopatadine 0.1% Rescue Treatment
    • Drug: Mometasone 50 mcg Rescue Treatment
    • Drug: Prednisone 5 mg Rescue Treatment
    • Drug: Albuterol sulfate 108 mcg
    • Drug: Fluticasone propionate 44 mcg
    • Drug: Prednisone 5 mg
  • Experimental: SCH 697243
    Interventions:
    • Biological: SCH 697243
    • Drug: Loratadine 10 mg Rescue Treatment
    • Drug: Olopatadine 0.1% Rescue Treatment
    • Drug: Mometasone 50 mcg Rescue Treatment
    • Drug: Prednisone 5 mg Rescue Treatment
    • Drug: Albuterol sulfate 108 mcg
    • Drug: Fluticasone propionate 44 mcg
    • Drug: Prednisone 5 mg
Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011 Jan;127(1):72-80, 80.e1-2. doi: 10.1016/j.jaci.2010.11.035.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
439
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants must be 18 to 65 years of age, of either sex, and of any race.
  • Participants must have a clinical history of significant allergic rhinoconjunctivitis to grass (with or without asthma) diagnosed by a physician and have received treatment for their disease during the previous GPS.
  • Participants must have a positive skin prick test response (average wheal diameter >=5 mm larger than the saline control after 15 to 20 minutes) to Phleum pratense at the Screening Visit.
  • Participants must be positive for specific IgE against Phleum pratense (>=IgE Class 2) at the Screening Visit.
  • Participants must have an FEV1 >=70% of predicted value at the Screening Visit.
  • Participants' safety laboratory tests, vital signs and ECG conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor.
  • Participant must be willing to give written informed consent and be able to adhere to dose and visit schedules.
  • Female participants of childbearing potential must be using a medically acceptable and adequate form of birth control. These include:

    • hormonal contraceptives as prescribed by a physician (oral, hormonal vaginal ring, hormonal implant or depot injectable);
    • medically prescribed intra-uterine device;
    • medically prescribed topically-applied transdermal contraceptive patch;
    • double-barrier method (eg, condom in combination with a spermicide); vasectomy and tubal ligation should each be considered as single barrier.
  • Female participants of childbearing potential should be counseled in the appropriate use of birth control while in the study. Female participants who are not currently sexually active must agree and consent to use one of the above-mentioned methods if they become sexually active while participating in the study.
  • Female participants of childbearing potential must have a negative urine pregnancy test at the Screening Visit in order to be considered eligible for enrollment.

Exclusion Criteria:

  • Participants with a clinical history of symptomatic seasonal allergic rhinitis and/or asthma, having received regular medications due to another allergen during or potentially overlapping the GPS.
  • Participants with a clinical history of significant symptomatic perennial allergic rhinitis and/or asthma having received regular medication due to an allergen to which the subject is regularly exposed.
  • Participants with sufficient pre-seasonal data in the observational phase will not be eligible to continue in the treatment phase if the subject: 1) does not experience an increase in rhinoconjunctivitis symptom score of equal to or greater than 4 above the pre-seasonal average symptom score for at least 2 days, 2) does not use allergy rescue medication for at least 2 days, during the observational phase Year 1 2008 GPS.
  • Participants that received an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms).
  • Participants with a clinical history of severe asthma.
  • Participants with history of anaphylaxis with cardiorespiratory symptoms.
  • Participants with a history of self-injectable epinephrine use.
  • Participants with a history of chronic urticaria and angioedema.
  • Participants with clinical history of chronic sinusitis during the 2 years prior to the Screening Visit.
  • Participants with current severe atopic dermatitis.
  • Female participants who are breast-feeding, pregnant, or intending to become pregnant.
  • Participatns who have had previous treatment by immunotherapy with grass pollen allergen or any other allergen within the 5 years prior to the Screening Visit.
  • Participants with a known history of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (except for Phleum pratense), rescue medications, or self-injectable epinephrine.
  • Participants with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study. Specific examples include but are not limited to hypertension being treated with beta blockers, coronary artery disease, arrhythmia, stroke, ocular conditions requiring topical beta blockers, any condition requiring the use of beta blockers.
  • Participants that have used any investigational drugs within 30 days of the Screening Visit.
  • Participants that are participating in any other clinical study.
  • Participants that are a family member of the investigational study staff conducting this study.
  • Participants that are unable to meet medication washout requirements as listed in the protocol.
  • Participants that are unlikely to be able to complete the trial, for any reason, or likely to travel for extended periods of time during the GPS, which in the opinion of the investigator will compromise the data.
  • Participants with a clinically significant abnormal vital sign or laboratory value that would preclude participation in the study.
  • Participants participating in this study may not participate in this same study at another investigational site.
  • Participants must not be randomized into this study more than once.
  • Participants who are unable to or will not comply with the use of self-injectable epinephrine.
  • Participants that may be at greater risk of developing adverse reactions after epinephrine administration.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00562159
P05238, 3727105
Yes
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP